Adults 18 to 70, any sex, with Post COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Extreme Fatigue (ANCOVA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Extreme fatigue. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure extreme fatigue has one end labeled "no fatigue" and the other end labeled "worst fatigue". The patient then marks a point on the line to indicate their current level of fatigue. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (fatigue).
Group
Value
95% CI
HB-adMSCs
-2.376
± 0.496
Placebo
-2.430
± 0.529
Changes From Baseline in Visual Analog Scale of Neurological Symptoms.. - Brain Fog (ANCOVA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Brain fog. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure brain fog has one end labeled "no brain fog" and the other end labeled "worst brain fog". The patient then marks a point on the line to indicate their current level of brain fog. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (brain fog).
Group
Value
95% CI
HB-adMSCs
-1.908
± 0.462
Placebo
-1.736
± 0.493
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Headache (ANCOVA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Headache. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure Headache has one end labeled "no headache" and the other end labeled "worst headache". The patient then marks a point on the line to indicate their current level of Headache. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (headache).
Group
Value
95% CI
HB-adMSCs
-0.755
± 0.348
Placebo
-1.154
± 0.371
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Sleep Disturbances (ANCOVA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Sleep disturbances. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure sleep disturbance has one end labeled "no sleep disturbance" and the other end labeled "worst sleep disturbance". The patient then marks a point on the line to indicate their current level of sleep disturbance. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (sleep disturbance).
Group
Value
95% CI
HB-adMSCs
-2.005
± 0.486
Placebo
-2.547
± 0.518
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Loss of Taste (ANCOVA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Loss of taste. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure loss of taste has one end labeled "no loss of taste" and the other end labeled "worst loss of taste". The patient then marks a point on the line to indicate their current level of loss of taste. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (loss of taste).
Group
Value
95% CI
HB-adMSCs
-0.509
± 0.314
Placebo
-0.462
± 0.335
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Loss of Smell (ANCOVA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Loss of smell. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure loss of smell has one end labeled "no loss of smell" and the other end labeled "worst loss of smell". The patient then marks a point on the line to indicate their current level of loss of smell. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (loss of smell).
Group
Value
95% CI
HB-adMSCs
-0.623
± 0.241
Placebo
-0.463
± 0.258
Changes From Baseline in Visual Analog Scale of Neurological Symptoms - Extreme Fatigue (RMA Model)Primary· Baseline to Week 26
Clinically significant changes in Visual Analog Scale. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure extreme fatigue has one end labeled "no fatigue" and the other end labeled "worst fatigue". The patient then marks a point on the line to indicate their current level of fatigue. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (fatigue).
Infusion 2 (Week 2)
Group
Value
95% CI
HB-adMSCs
-1.010
± 0.406
Placebo
-0.772
± 0.428
Infusion 3 (Week 6)
Group
Value
95% CI
HB-adMSCs
-1.214
± 0.438
Placebo
-1.439
± 0.468
Infusion 4 (Week 10)
Group
Value
95% CI
HB-adMSCs
-2.010
± 0.463
Placebo
-2.018
± 0.494
EOS (Week 26)
Group
Value
95% CI
HB-adMSCs
-2.330
± 0.490
Placebo
-2.492
± 0.522
Changes From Baseline in Visual Analog Scale of Neurological Symptoms.. - Brain Fog (RMA Model)Primary· Baseline to Week 26
Clinically significant changes in Visual Analog Scale - Brain fog. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure brain fog has one end labeled "no brain fog" and the other end labeled "worst brain fog". The patient then marks a point on the line to indicate their current level of brain fog. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (brain fog).
Infusion 2 (Week 2)
Group
Value
95% CI
HB-adMSCs
-1.134
± 0.352
Placebo
-0.944
± 0.371
Infusion 3 (Week 6)
Group
Value
95% CI
HB-adMSCs
-1.425
± 0.377
Placebo
-0.837
± 0.402
Infusion 4 (Week 10)
Group
Value
95% CI
HB-adMSCs
-2.281
± 0.419
Placebo
-1.532
± 0.446
End of Study (Week 26)
Group
Value
95% CI
HB-adMSCs
-1.827
± 0.467
Placebo
-1.818
± 0.497
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Headache (RMA Model)Primary· Baseline to Week 26
Clinically significant changes in Visual Analog Scale - Headache. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure Headache has one end labeled "no headache" and the other end labeled "worst headache". The patient then marks a point on the line to indicate their current level of Headache. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (headache).
Infusion 2 (Week 2)
Group
Value
95% CI
HB-adMSCs
-0.362
± 0.400
Placebo
-0.548
± 0.422
Infusion 3 (Week 6)
Group
Value
95% CI
HB-adMSCs
-0.504
± 0.388
Placebo
-0.648
± 0.414
Infusion 4 (Week 10)
Group
Value
95% CI
HB-adMSCs
-0.696
± 0.385
Placebo
-0.870
± 0.411
End Of Study (Week 26)
Group
Value
95% CI
HB-adMSCs
-0.741
± 0.346
Placebo
-1.181
± 0.369
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Sleep Disturbances (RMA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Sleep Disturbances. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure sleep disturbance has one end labeled "no sleep disturbance" and the other end labeled "worst sleep disturbance". The patient then marks a point on the line to indicate their current level of sleep disturbance. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (sleep disturbance).
Infusion 2 (Week 2)
Group
Value
95% CI
HB-adMSCs
-1.331
± 0.340
Placebo
-0.730
± 0.357
Infusion 3 (Week 6)
Group
Value
95% CI
HB-adMSCs
-1.845
± 0.462
Placebo
-1.813
± 0.492
Infusion 4 (Week 10)
Group
Value
95% CI
HB-adMSCs
-2.028
± 0.466
Placebo
-2.095
± 0.497
End of Study (Week 26)
Group
Value
95% CI
HB-adMSCs
-2.016
± 0.479
Placebo
-2.551
± 0.510
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Loss of Taste (RMA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Loss of taste. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure loss of taste has one end labeled "no loss of taste" and the other end labeled "worst loss of taste". The patient then marks a point on the line to indicate their current level of loss of taste. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (loss of taste).
Infusion 2 (Week 2)
Group
Value
95% CI
HB-adMSCs
-0.450
± 0.234
Placebo
0.235
± 0.247
Infusion 3 (Week 6)
Group
Value
95% CI
HB-adMSCs
-0.372
± 0.325
Placebo
0.523
± 0.346
Infusion 4 (Week 10)
Group
Value
95% CI
HB-adMSCs
-0.654
± 0.339
Placebo
-0.365
± 0.362
End of Study (Week 26)
Group
Value
95% CI
HB-adMSCs
-0.569
± 0.318
Placebo
-0.408
± 0.339
Changes From Baseline in Visual Analog Scale of Neurological Symptoms. - Loss of Smell (RMA Model)Primary· Baseline to Weeks 26
Clinically significant changes in Visual Analog Scale - Loss of smell. A VAS is a straight line with two end points that represent the extremes of a range. This VAS used to measure loss of smell has one end labeled "no loss of smell" and the other end labeled "worst loss of smell". The patient then marks a point on the line to indicate their current level of loss of smell. The minimum score is a 0 and the maximum score is a 10. A higher score indicates a worse outcome (loss of smell).
Infusion 2 (Week 2)
Group
Value
95% CI
HB-adMSCs
-0.336
± 0.273
Placebo
0.617
± 0.288
Infusion 3 (Week 6)
Group
Value
95% CI
HB-adMSCs
-0.112
± 0.264
Placebo
-0.013
± 0.281
Infusion 4 (Week 10)
Group
Value
95% CI
HB-adMSCs
-0.678
± 0.242
Placebo
-0.196
± 0.258
End Of Study (Week 26)
Group
Value
95% CI
HB-adMSCs
-0.653
± 0.241
Placebo
-0.438
± 0.256
Adverse events — posted to ClinicalTrials.gov
Time frame: Week 0 (Infusion 1) through Week 26 (End of Study).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10 weeks with two follow-up visits and an end of study visit at week 26.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
Other recruiting trials for Post COVID-19 Syndrome
Currently open trials in the same condition.
NCT07110714 — Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients
· NA
· recruiting
NCT07051954 — Effectiveness of Functional Respiratory Muscle Training in Post-COVID-19 Syndrome
· NA
· recruiting
Other Hope Biosciences Research Foundation trials
Trials by the same sponsor.
NCT05116540 — Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis
· Phase 2
· completed
NCT04995081 — Clinical Trial for Parkinson's Disease Using Allogeneic HB-adMSCs (Early and Moderate PD)
· Phase 2
· completed
NCT04928287 — Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)
· Phase 2
· completed
NCT04362189 — Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19
· Phase 2
· terminated
NCT04348435 — A Randomized, Double-Blind, Single Center, Efficacy and Safety Study of Allogeneic HB-adMSCs Against COVID-19.
· Phase 2
· completed
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Hope Biosciences Research Foundation
Last refreshed: 26 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05126563.